Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sesiclenegene cosaparvovec is an investigational AAV-based gene therapy designed for the treatment of neuronal ceroid lipofuscinosis type 6 (CLN6), a form of Batten disease. This therapy uses an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the CLN6 gene to patient cells, aiming to restore or modulate the function of the defective CLN6 transmembrane endoplasmic reticulum protein. The mechanism involves gene transfer and modulation of CLN6 protein activity. Sesiclenegene cosaparvovec has received PRIME designation in the EU and is currently in Phase 2 clinical development for neuronal ceroid-lipofuscinoses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sesiclenegene cosaparvovec.